NAYA (NAYA Biosciences) Forward P/E Multiple
NAYA Biosciences relies on external financing and grants, as it currently lacks operating income. The team brings together experts in reproductive medicine and oncology, attracted by stock option programs. The company's future P/E metric reflects the intensive validation of bispecific antibodies, with the value held at 0.00, which helps assess market expectations for the R&D pipeline.
Summary analytical data breakdowns for NAYA Biosciences Corp (NAYA)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital NAYA Biosciences|NAYA - Long-Term Liabilities to Capital|Short-Term Debt to Equity NAYA Biosciences|NAYA - Company Aggregate Debt|Debts to Book Capitalization NAYA Biosciences Inc|NAYA - Company Long-Term Debts|Company Current Liabilities NAYA Biosciences|Quick Ratio nayabiosciences.com
- financial results and valuation multiples details:
NAYA - Net Profit|Future Profit NAYA Biosciences|NAYA - Company Value to Net Income|Forward P/E Multiple NAYA Bio|NAYA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple NAYA Biosciences Inc|NAYA - Operating income before deduction of amortization|Earnings per share for the last twelve months NAYA Biosciences|NAYA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months nayabiosciences.com|NAYA - Expected net earnings per share growth this year|Earnings growth forecast for next year NAYA Biosciences
- sales volume and revenue indicators:
Summary company analytics:NAYA Biosciences Inc.
The forward P/E compares current market capitalization with expected net income, reflecting market expectations regarding future business efficiency. By analyzing the current forward P/E level of NAYA Biosciences (NAYA), an investor performs a stress test on asset resilience, which is critical for NAYA Biosciences, as its valuation currently depends on the speculative assessment of success in deploying its oncology portfolio.
Analysis of competing companies
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Future Price to Earnings Y-mAbs Therapeutics (YMAB)|aurabiosciences.com - Price to Future Earnings Ratio|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Forward P/E Multiple Accuray Inc ARAY|SLS: Projected Price to Earnings|Projected Price to Earnings Ratio Actuate Therapeutics Inc|CTOR: Forward P/E Multiple|TuHURA Biosciences (HURA) - Forward P/E Multiple|Projected Price to Earnings TARA|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|Future Price to Earnings TCRX (tscan.com)|Forward P/E Multiple CSBR (Champions Oncology, Inc.)|Market Cap to Projected Earnings XBiotech Inc (XBIT)|CVM - Future Price to Earnings|Projected Price to Earnings Ratio OS Therapies Inc.|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|ANL (Adlai Nortye Ltd) - Forward P/E Multiple|Projected Price to Earnings verupharma.com (VERU)|Forward P/E Multiple TPST|Market Cap to Projected Earnings xiliotx.com|Forward P/E Multiple RENB (Renovaro)|Mural Oncology PLC (MURA) - Projected Price to Earnings Ratio|KAPA - Future Price to Earnings|OKUR (OnKure Therapeutics Inc) - Price to Future Earnings Ratio|GDTC: Forward P/E Multiple|Projected Price to Earnings Curis|APLM (Apollomics Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio Tharimmune Corporation THAR|Future Price to Earnings Advanced Biomed Inc (ADVB)|Market Cap to Projected Earnings genprex.com|Future Price to Earnings Calidi Biotherapeutics, Inc. CLDI|SBFM: Price to Future Earnings Ratio|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT (Purple Biotech) - Projected Price to Earnings|Projected Price to Earnings Ratio American Oncology Network, Inc. (AONC)|BGNE (BeiGene) - Forward P/E Multiple|Forward P/E Multiple Checkpoint Therapeutics Inc.|Forward P/E Multiple ELEV|Projected Price to Earnings icadmed.com ICAD|Forward P/E Multiple IKNA (Ikena Oncology)|Forward P/E Multiple notablelabs.com NTBL|VIRX - Future Price to Earnings|MOR (MorphoSys Inc) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
